657 results on '"Clarke, Blaise A."'
Search Results
52. Supplementary Figure 2 from Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
53. Supplementary Methods, Legends for Figures 1-5 from Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
54. Supplementary Figure 5 from Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
55. Supplementary Figure 4 from Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
56. Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers
57. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study
58. Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC)
59. Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study
60. Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers
61. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group
62. Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review
63. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
64. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia
65. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer
66. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs
67. 1/#337 Molecular classification of endometrial cancers using an integrative DNA sequencing panel
68. Efficacy evaluation of a novel vectorized anti‐tau antibody, targeting a C‐terminal phospho‐tau epitope, using systemic dosing of a blood brain barrier penetrant AAV capsid in mouse models of tauopathies.
69. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification
70. Perspectives in Endometrial Pathology
71. Clear Cell Carcinoma of Uterine Cervix: A Clinicopathologic Review and Molecular Characterization
72. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts
73. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin
74. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas
75. Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis
76. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
77. Uterine adenosarcomas: A dual-institution update on staging, prognosis and survival
78. Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma
79. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
80. A Triage Assessment Strategy for the Management of Women With Endometrial Cancer
81. The Significance of Tumoral ERCC1 Status in Patients With Locally Advanced Cervical Cancer Treated With Chemoradiation Therapy: A Multicenter Clinicopathologic Analysis
82. Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors
83. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors
84. Additional file 2 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
85. Additional file 1 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
86. Additional file 4 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
87. Additional file 3 of Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma
88. Calculator for ovarian carcinoma subtype prediction
89. Ovarian immature teratoma: Treatment and outcome in a single institutional cohort
90. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
91. Ovarian hilar proliferations resembling Sertoli cell tumours: microscopic neoplasms or non-neoplastic remnants?
92. Impact of Neoadjuvant Chemotherapy on Somatic Mutation Status in High-grade Serous Ovarian Carcinoma
93. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs
94. Mutations in IDH1 and IDH2 are not present in sporadic ovarian sex cord–stromal tumours*
95. Microscopic extraovarian sex cord proliferations: an undescribed phenomenon
96. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
97. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing
98. Canadian Association of Pathologists–Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: Guidelines for the Preparation, Release, and Storage of Unstained Archived Diagnostic Tissue Sections for Immunohistochemistry
99. Validation of BRCA testing on cytologic samples of high‐grade serous carcinoma
100. Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.